Social Sentiment Ticker Powered by AI

DOW/USDDow Jones Industrial Average/USD
38,459.08
0.00
neutral
SPX/USDStandard & Poor’s 500/USD
5,199.06
0.00
neutral
NDX/USDNASDAQ-100/USD
18,307.98
0.00
neutral
BTC/USDBitcoin – United States Dollar/USD
70,838.79
+792.39(1.13%)
bullish
ETH/USDEthereum – United States Dollar/USD
3,534.62
+31.56(0.90%)
bullish
XRP/USDRipple – United States Dollar/USD
0.61
-0.00(0.03%)
bearish
DOGE/USDDogecoin – United States Dollar/USD
0.20
+0.01(2.77%)
bullish
AAPL/USDApple Inc./USD
174.21
-0.84(0.48%)
bearish
GOOGL/USDAlphabet Inc. Class A Common Stock/USD
158.59
-0.83(0.52%)
bearish
TSLA/USDTesla, Inc. Common Stock/USD
173.00
-1.60(0.92%)
bearish
META/USDMeta Platforms, Inc. Class A Common Stock/USD
520.21
-2.95(0.56%)
bearish
NVDA/USDNvidia Corp/USD
902.59
-3.57(0.39%)
bearish
AMD/USDAdvanced Micro Devices/USD
167.84
-2.66(1.56%)
bearish
COIN/USDCoinbase Global, Inc. Class A Common Stock/USD
261.56
-1.45(0.55%)
bearish
NFLX/USDNetFlix Inc/USD
629.65
+0.87(0.14%)
bullish

Social Sentiment Ticker Powered by AI

DOW/USDDow Jones Industrial Average/USD
38,459.08
0.00
neutral
SPX/USDStandard & Poor’s 500/USD
5,199.06
0.00
neutral
NDX/USDNASDAQ-100/USD
18,307.98
0.00
neutral
BTC/USDBitcoin – United States Dollar/USD
70,838.79
+792.39(1.13%)
bullish
ETH/USDEthereum – United States Dollar/USD
3,534.62
+31.56(0.90%)
bullish
XRP/USDRipple – United States Dollar/USD
0.61
-0.00(0.03%)
bearish
DOGE/USDDogecoin – United States Dollar/USD
0.20
+0.01(2.77%)
bullish
AAPL/USDApple Inc./USD
174.21
-0.84(0.48%)
bearish
GOOGL/USDAlphabet Inc. Class A Common Stock/USD
158.59
-0.83(0.52%)
bearish
TSLA/USDTesla, Inc. Common Stock/USD
173.00
-1.60(0.92%)
bearish
META/USDMeta Platforms, Inc. Class A Common Stock/USD
520.21
-2.95(0.56%)
bearish
NVDA/USDNvidia Corp/USD
902.59
-3.57(0.39%)
bearish
AMD/USDAdvanced Micro Devices/USD
167.84
-2.66(1.56%)
bearish
COIN/USDCoinbase Global, Inc. Class A Common Stock/USD
261.56
-1.45(0.55%)
bearish
NFLX/USDNetFlix Inc/USD
629.65
+0.87(0.14%)
bullish

Download App

For a Limited Time Get 1 Month Free of TradeZing+

For a Limited Time Get 1 Month Free of TradeZing+

Learn More
Back

Live Audio Room

No related audio room.

Related Events

No related events.


Latest Feed

0

April 12, 2024

13 mins ago

# of Events: 0

Wall Street Wobbles: Stock Futures Point To Slide As JPMorgan Tumbles 3% While Gold Surges Past $2,400 — Analyst Sees This As ‘Worst-Case’ Scenario For S&P 500 Pullback

The relief rally sparked by Thursday’s producer price index report is teetering on the edge. The mood has shifted back to cautiousness, with stock futures pointing towards a potential pullback in today’s final trading session of the week. Traders are meticulously analyzing each incoming piece of economic data to gauge the Federal Reserve’s next move. Upcoming consumer confidence data and speeches by Fed officials are likely to garner significant market interest. Big bank earnings released so far have triggered negative reactions, and this could cast a cloud on the upcoming reporting season and its impact on the market. Futures Performance On Thursday ( as of 6:30 a.m. EDT) Futures Performance (+/-) Nasdaq 100 -0.53% S&P 500 -0.43% Dow -0.27% R2K -0.52% In premarket trading on Thursday, the SPDR S&P 500 ETF Trust (NYSE:SPY) fell 0.30% to $516.43, and the Invesco QQQ ETF (NASDAQ:QQQ) slipped 0.43% to $443.45, according to Benzinga Pro data. Cues From Previous Session: Producer price data released on Thursday came in slightly lower than anticipated, initially triggering a knee-jerk negative reaction in the market. However, major averages reversed course later in the morning, steadily climbing before consolidating in late-day trading. The Nasdaq Composite and S&P 500 closed solidly higher, with the Nasdaq reaching a new closing high driven by strength in IT and communication services stocks. Conversely, the Dow Jones Industrial Average closed with a slight negative bias, marking its fourth consecutive down day.

AMD

BLK

C

GL

INTC

JPM

QQQ

SPY

STT

WFC

0

164980

News

0

April 12, 2024

18 mins ago

# of Events: 0

Why Tilray Brands Stock Fell 26.9% This Week

The cannabis lifestyle products company announced mixed results and lowered its full-year outlook.

TLRY

0

164981

News


Related on Reddit


Related on X


Related on YouTube

4

April 2, 2024
1 week ago

Critical Insights From Nurix Therapeutics Analyst Ratings: What You Need To Know

In the preceding three months, 8 analysts have released ratings for Nurix Therapeutics (NASDAQ:NRIX), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 2 1 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Nurix Therapeutics, presenting an average target of $24.38, a high estimate of $31.00, and a low estimate of $10.00. A 0.08% drop is evident in the current average compared to the previous average price target of $24.40. Investigating Analyst Ratings: An Elaborate Study An in-depth analysis of recent analyst actions unveils how financial experts perceive Nurix Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gil Blum Needham Maintains Buy $31.00 $31.00 Gil Blum Needham Maintains Buy $31.00 – Terence Flynn Morgan Stanley Raises Equal-Weight $10.00 $9.00 Robert Burns HC Wainwright & Co. Lowers Buy $19.00 $35.00 Derek Archila Wells Fargo Lowers Overweight $20.00 $23.00 Gregory Renza RBC Capital Lowers Outperform $22.00 $24.00 Gil Blum Needham Maintains Buy $31.00 – Gil Blum Needham Maintains Buy $31.00 – Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their reaction to recent developments related to Nurix Therapeutics. This information provides a snapshot of how …Full story available on Benzinga.com

Continue Reading

Feed Topics

News

Feed Tags

Subscribe

Notify of


2 Comments


Oldest

Newest
Most Voted

Inline Feedbacks
View all comments

Pilar

9 days ago

Looks like Nurix Therapeutics is under the analyst microscope lately

Sarahbuidini

9 days ago

It’s always fascinating to see how the market interprets the potential of biotech firms like this.

Copied